Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Deciphera Pharmaceuticals, Inc. (DCPH)
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
deciphera.com/investor-relations
Company Research
Source: Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced underwritten public offering, which closed on June 11, 2018, have exercised in full their option to purchase an additional 645,000 shares of Deciphera’s common stock. Including this option exercise, total gross proceeds to Deciphera from the offering of an aggregate 4,945,000 shares at a public offering price of $40.00 per share will be approximately $198 million, before deducting the underwriting discounts and commissions and other offering expenses. J.P. Morgan and Piper Jaffray & Co. acted as joint book-running managers for the offering. Canaccord Genuity LLC and JMP Securities LLC acted as lead managers, and Nomura Securities International, Inc. and Raymond
Show less
Read more
Impact Snapshot
Event Time:
DCPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCPH alerts
High impacting Deciphera Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
DCPH
News
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) was downgraded by analysts at Leerink Partnrs from an "outperform" rating to a "market perform" rating.MarketBeat
- XBI: The 2 Things Biotech Needs To Move Higher [Seeking Alpha]Seeking Alpha
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, HTLF, UMBF, TBNKAccesswire
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its "neutral" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its "market perform" rating re-affirmed by analysts at JMP Securities.MarketBeat
DCPH
Earnings
- 2/6/24 - Beat
DCPH
Sec Filings
- 4/30/24 - Form SC
- 4/30/24 - Form SC14D9C
- 4/29/24 - Form SC14D9C
- DCPH's page on the SEC website